ストックスクリーナーアプリを入手
19.45
0.49%
-0.08
前日終値:
$19.53
開ける：
$19.44
24時間の取引高:
49,851
Relative Volume:
0.14
時価総額：
$788.66M
収益：
-
当期純損益:
$-81.05M
株価収益率:
-7.4146
EPS:
-2.6232
ネットキャッシュフロー:
$-68.97M
1週間 パフォーマンス:
+11.76%
1か月 パフォーマンス:
-11.86%
6か月 パフォーマンス:
-25.85%
1年 パフォーマンス:
-20.22%
1日の値動き範囲:
$19.28
$19.99
1週間の範囲:
$16.10
$19.99
52週間の値動き範囲:
$15.47
$36.37
Arrivent Biopharma Inc Stock (AVBP) Company Profile
AVBP を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
19.44 | 792.31M | 0 | -81.05M | -68.97M | -2.6232 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.20 | 100.71B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
578.50 | 61.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.93 | 58.84B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
664.06 | 40.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
325.48 | 38.20B | 3.81B | -644.79M | -669.77M | -6.24 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-10 | 再開されました | Goldman | Buy |
| 2025-03-20 | 開始されました | B. Riley Securities | Buy |
| 2025-03-10 | 開始されました | Guggenheim | Buy |
| 2024-07-22 | 開始されました | Oppenheimer | Outperform |
| 2024-04-30 | 開始されました | H.C. Wainwright | Buy |
| 2024-02-20 | 開始されました | Citigroup | Buy |
| 2024-02-20 | 開始されました | Goldman | Buy |
| 2024-02-20 | 開始されました | Jefferies | Buy |
すべてを表示
Arrivent Biopharma Inc (AVBP) 最新ニュース
Predicting ArriVent BioPharma Inc. trend using moving averagesPrice Action & Growth Focused Investment Plans - Newser
What makes ArriVent BioPharma Inc. stock price move sharplyJuly 2025 Volume & AI Optimized Trade Strategies - Newser
Trend analysis for ArriVent BioPharma Inc. this weekTrade Risk Summary & Free Growth Oriented Trading Recommendations - Newser
Is ArriVent BioPharma Inc. trending in predictive chart models2025 Support & Resistance & Weekly Momentum Picks - Newser
Will ArriVent BioPharma Inc. outperform the market2025 Analyst Calls & Weekly Top Gainers Alerts - Newser
Can you recover from losses in ArriVent BioPharma Inc.Weekly Market Outlook & Weekly Chart Analysis and Trade Guides - Newser
Backtesting results for ArriVent BioPharma Inc. trading strategiesOptions Play & Community Consensus Picks - Newser
Custom strategy builders for tracking ArriVent BioPharma Inc.Weekly Earnings Recap & Free Expert Approved Momentum Trade Ideas - Newser
Candlestick signals on ArriVent BioPharma Inc. stock todayForecast Cut & Technical Pattern Recognition Alerts - Newser
How to interpret RSI for ArriVent BioPharma Inc. stockMarket Activity Summary & Free High Return Stock Watch Alerts - Newser
What machine learning models say about ArriVent BioPharma Inc.Market Performance Summary & Fast Entry Momentum Alerts - Newser
Does ArriVent BioPharma Inc. fit your quant trading modelWeekly Market Outlook & Safe Entry Trade Signal Reports - Newser
ArriVent BioPharma Posts Q2 Loss as Cancer Drug Pipeline Advances Toward Key Milestones - MSN
News impact scoring models applied to ArriVent BioPharma Inc.Weekly Profit Analysis & Long-Term Safe Investment Plans - Newser
Will ArriVent BioPharma Inc. price bounce be sustainableMarket Activity Report & Long-Term Safe Investment Plans - Newser
Comparing ArriVent BioPharma Inc. in custom built stock radars2025 Winners & Losers & Long-Term Growth Stock Strategies - Newser
Advanced analytics toolkit walkthrough for ArriVent BioPharma Inc.Product Launch & Safe Entry Trade Signal Reports - Newser
ArriVent BioPharma Inc. recovery potential after sell offEarnings Recap Summary & Risk Managed Investment Entry Signals - Newser
Can trapped investors hope for a rebound in ArriVent BioPharma Inc.Gap Down & Weekly Setup with High ROI Potential - Newser
ArriVent BioPharma Inc. Stock Lags Behind Sector Benchmarks2025 Price Momentum & Fast Moving Trade Plans - beatles.ru
ArriVent BioPharma Inc. Recovery Hinges on Volume Breakout2025 Biggest Moves & Weekly High Return Forecasts - metal.it
Omega Advisors' Q2 Holdings: New Buys, Exits, and Stakes Increased - AInvest
Cooperman’s Omega bought Atlas Energy and ArriVent in Q2 - TipRanks
ArriVent BioPharma Inc. Price Targets Raised After ReboundMarket Trend Review & Real-Time Sentiment Analysis - mustnews.co.kr
ArriVent Biopharma price target lowered to $33 from $40 at Citi - MSN
ArriVent BioPharma Advances Cancer Therapeutics Pipeline - MSN
Mineralys: HC Wainwright Raises PT to $42, Maintains Buy Rating - AInvest
Guggenheim Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $45 - 富途牛牛
ArriVent BioPharma Inc. stock retracement – recovery analysisM&A Rumor & Real-Time Volume Trigger Notifications - Newser
ArriVent Biopharma price target raised to $42 from $40 at H.C. Wainwright - TipRanks
A Quick Look at Today's Ratings for ArriVent BioPharma(AVBP.US), With a Forecast Between $33 to $45 - 富途牛牛
H.C. Wainwright raises ArriVent BioPharma stock price target to $42 on NSCLC drug potential - Investing.com Canada
ArriVent BioPharma Inc. stock trend outlook and recovery pathFree Short Term High Yield Stock Tips - Newser
ArriVent Biopharma sees cash runway into mid-2027 - TipRanks
Why ArriVent BioPharma Inc. stock attracts strong analyst attentionFree Low Capital High Return Stock Plans - Newser
ArriVent Biopharma reports Q2 EPS (90c), consensus (71c) - TipRanks
Does ArriVent BioPharma Inc. qualify in momentum factor screeningSector Rotation Strategy for Smart Traders - Newser
Understanding ArriVent BioPharma Inc.’s price movementFree Breakout Entry Signal Confirmation Tool - Newser
ArriVent BioPharma Reports Q2 GAAP EPS of -$0.90, Misses Expectations - AInvest
ArriVent BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
ArriVent Posts Wider Loss in Fiscal Q2 - The Motley Fool
ArriVent Posts Wider Loss in Fiscal Q2 - The Globe and Mail
ArriVent BioPharma, Inc. SEC 10-Q Report - TradingView
ArriVent's Lung Cancer Drug Shows Promise in Phase 1b Trial, Reports $335M Cash Position - Stock Titan
ArriVent BioPharma (AVBP) Projected to Post Quarterly Earnings on Wednesday - Defense World
How hedge fund analytics apply to ArriVent BioPharma Inc. stockEntry Confirmation Using Short-Term Forecasting - Newser
Arrivent Biopharma Inc (AVBP) 財務データ
収益
当期純利益
現金流量
EPS
Arrivent Biopharma Inc (AVBP) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| LaChapelle Robin | Chief Operating Officer |
Sep 19 '24 |
Option Exercise |
3.28 |
27,566 |
90,481 |
124,583 |
0.14%
0.30%
大文字化:
|
ボリューム (24 時間):